Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients

Transplant International

Volumn 26, Issue 2, 2013, Pages 121-130

  Bartel, Gregor ^a   Wahrmann, Markus ^a   Schwaiger, Elisabeth ^a   Kikic̈, Željko ^a   Winzer, Christine ^a   Hörl, Walter H ^a   Mühlbacher, Ferdinand ^a   Hoke, Matthias ^a   Zlabinger, Gerhard J ^b   Regele, Heinz ^c   Böhmig, Georg A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

C4d; complement activation; desensitization; HLA antibodies; rejection

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD GROUP TYPING; CONTROLLED STUDY; CYTOTOXICITY TEST; FEMALE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE ANTIGEN BEAD; SOLID PHASE EXTRACTION;

ADSORPTION; ADULT; ANTIBODIES; COHORT STUDIES; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872543819     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12000     Document Type: Article

References (50)

1. Terasaki PI,. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
2. Colvin RB,. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
3. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
4. Vo AA, Lukovsky M, Toyoda M, et al,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
5. Bartel G, Wahrmann M, Regele H, et al,. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant. 2010; 10: 2033.
6. Montgomery RA, Lonze BE, King KE, et al,. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
7. Morath C, Beimler J, Opelz G, et al,. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506.
8. Bartel G, Schwaiger E, Böhmig GA,. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int 2011; 24: 1142.
9. Tait BD, Hudson F, Cantwell L, et al,. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009; 14: 247.
10. Vaidya S, Partlow D, Susskind B, Noor M, Barnes T, Gugliuzza K,. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 2006; 82: 1524.
11. Zachary AA, Sholander JT, Houp JA, Leffell MS,. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574.
12. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681.
13. Wahrmann M, Bartel G, Exner M, et al,. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22: 982.
14. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
15. van den Berg-Loonen EM, Billen EV, Voorter CE, et al,. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
16. Gloor JM, Winters JL, Cornell LD, et al,. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582.
17. Wahrmann M, Exner M, Regele H, et al,. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 2003; 275: 149.
18. Smith JD, Hamour IM, Banner NR, Rose ML,. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
19. Bartel G, Regele H, Wahrmann M, et al,. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8: 2652.
20. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB,. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342.
21. Chen G, Sequeira F, Tyan DB,. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849.
22. Böhmig GA, Exner M, Habicht A, et al,. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091.
23. Sis B, Mengel M, Haas M, et al,. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
24. Mengel M, Sis B, Haas M, et al,. Banff 2011 Meeting Report: new concepts in antibody-mediated rejection. Am J Transplant 2011; 12: 563.
25. Stegall MD, Diwan T, Raghavaiah S, et al,. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405.
26. Le Bas-Bernardet S, Hourmant M, Valentin N, et al,. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003; 75: 477.
27. Bartel G, Wahrmann M, Exner M, et al,. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007; 83: 727.
28. Kosmoliaptsis V, Bradley JA, Peacock S, Chaudhry AN, Taylor CJ,. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation 2009; 87: 813.
29. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D,. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation 2011; 92: 510.
30. Cohen D, Colvin RB, Daha MR, et al,. Pros and cons for C4d as a biomarker. Kidney Int 2012; 81: 628.
31. Sis B, Campbell PM, Mueller T, et al,. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743.
32. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
33. Loupy A, Hill GS, Suberbielle C, et al,. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56.
34. Haas M,. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol 2011; 75: 271.
35. Zhang X, Reed EF,. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459.
36. Hirohashi T, Chase CM, Della Pelle P, et al,. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12: 313.
37. Smith RN, Kawai T, Boskovic S, et al,. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in cynomolgus monkeys. Am J Transplant 2008; 8: 1662.
38. Bartel G, Wahrmann M, Exner M, et al,. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8: 41.
39. Kimball PM, Baker MA, Wagner MB, King A,. Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011; 79: 1131.
40. Salama AD, Delikouras A, Pusey CD, et al,. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.
41. Higgins R, Hathaway M, Lowe D, et al,. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007; 84: 876.
42. Rose ML, West LJ,. Accommodation: does it apply to human leukocyte antigens? Transplantation 2012; 93: 244.
43. Gloor JM, Cosio FG, Rea DJ, et al,. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841.
44. Kraus ES, Parekh RS, Oberai P, et al,. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9: 1826.
45. Bächler K, Amico P, Hönger G, et al,. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254.
46. Loupy A, Suberbielle-Boissel C, Zuber J, et al,. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010; 89: 1403.
47. Hönger G, Wahrmann M, Amico P, Hopfer H, Böhmig GA, Schaub S,. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010; 89: 1471.
48. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB,. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12.
49. Bindon CI, Hale G, Bruggemann M, Waldmann H,. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168: 127.
50. Zou Y, Stastny P, Susal C, Dohler B, Opelz G,. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293.